Grassley And Baucus Turn Up Heat On GSK With Attack On Avandia Data Handling
This article was originally published in The Pink Sheet Daily
Executive Summary
Company's internal e-mails suggest GSK hid vital studies related to safety of Avandia relative to competitor, senators charge.
You may also be interested in...
Ingredients For Product Liability Litigation: From FDA Actions To Foreign Labels
What do plaintiffs lawyers look for in deciding whether to file a product liability suit against a pharmaceutical company?
Ingredients For Product Liability Litigation: From FDA Actions To Foreign Labels
What do plaintiffs lawyers look for in deciding whether to file a product liability suit against a pharmaceutical company?
Avandia Advisory Committee Re-Review Reflects Well On FDA
The FDA advisory committee re-review of cardiovascular safety risks with GlaxoSmithKline's Avandia (rosiglitazone) will not end calls from agency critics to create a separate drug safety center. However, the transparency of internal scientific disputes on display at the July 13-14 meeting and the committee's recommendations could take some ammunition away from those who assert the Center for Drug Evaluation and Research has given short shrift to safety issues